Patent classifications
C07K16/1036
Method of treating cancer using IL2R beta/common gamma chain antibodies
Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES
Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Endogenous retrovirus-k (ERVK) encodes an alternate envelope protein
The present disclosure relates to an endogenous Retrovirus K protein (ERVK) with an alternative envelope protein titled CTXLP. Said CTXLP peptide is represented by the sequences set forth in SEQ ID NO: 1. Additionally, antibodies that specifically recognize the epitope(s) set forth in SEQ ID NO:1 are and methods of use thereof and kits comprising the peptide set forth in SEQ ID NO:1 are also included in the present disclosure.
Methods for determining spatial and temporal gene expression dynamics in single cells
Transcriptomes of individual neurons provide rich information about cell types and dynamic states. However, it is difficult to capture rare dynamic processes, such as adult neurogenesis, because isolation from dense adult tissue is challenging, and markers for each phase are limited. Here, Applicants developed Nuc-seq, Div-Seq, and Dronc-Seq. Div-seq combines Nuc-Seq, a scalable single nucleus RNA-Seq method, with EdU-mediated labeling of proliferating cells. Nuc-Seq can sensitively identify closely related cell types within the adult hippocampus. Div-Seq can track transcriptional dynamics of newborn neurons in an adult neurogenic region in the hippocampus. Dronc-Seq uses a microfluidic device to co-encapsulate individual nuclei in reverse emulsion aqueous droplets in an oil medium together with one uniquely barcoded mRNA-capture bead. Finally, Applicants found rare adult newborn GABAergic neurons in the spinal cord, a non-canonical neurogenic region. Taken together, Nuc-Seq, Div-Seq and Dronc-Seq allow for unbiased analysis of any complex tissue.
Viral clearance by low pH hold
Methods for viral clearance using low pH hold based on a statistical design of experiment are provided. Several factors are evaluated to characterize the impacts of a low pH hold step for virus inactivation, including the factors of pH conditions, conductivity conditions, protein type, temperature, acid titrant, spike timing, and post-spike filtration. In addition to the effect of pH on virus inactivation, an increase in ionic strength through manipulating the conductivity can be a key component that influences virus inactivation kinetics.
ANTI-HERV-W ENVELOPE PROTEIN ANTIBODY FOR USE IN THE TREATMENT OF PSYCHOTIC DISEASES
The present invention relates to an antibody directed against HERV-W envelope protein (ENV) for use in the treatment of a group of patients diagnosed with a psychotic disease and characterized with a high level for a cytokine in a body fluid sample.
IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES
Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
Methods for producing peptides including HERV-W envelope motifs and for producing antibodies specific for the peptides
A peptide domain necessary for an interaction between an envelope of a virus belonging to an HERV-W interference group and an hASCT receptor comprises (i) an N-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 1 to SEQ ID No. 29, (ii) a C-terminus motif having an amino acid sequence selected from the group consisting of: SEQ ID No. 30 to SEQ ID No. 40, and (iii) at least one motif between the N-terminus and the C-terminus, and having an amino acid sequence selected from the group consisting of: SEQ ID No. 41, SEQ ID No. 42 and SEQ ID No. 73.
IL2RBETA/COMMON GAMMA CHAIN ANTIBODIES
Anti-CD122 and/or ?c antibodies and fragments thereof are disclosed. Also disclosed are compositions comprising such antibodies and fragments, and uses and methods using the same.
ANTIGEN BINDING MOLECULES AND METHODS OF USE
The present disclosure describes antigen binding molecules, including antibodies, that specifically bind to the anti-CD20 scFv-14 or Gibbon ape leukemia virus gp70 protein, as well as molecules comprising the described sequences and cells presenting such molecules. The antigen binding molecules may be used in research, diagnostic, clinical, and other applications.